• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Technologies
    • Balloons
    • Brain-computer interfaces
    • Cardiac Implants
    • Catheters
    • Endoscopes
    • Heart valves
    • Pulsed Field Ablation
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Molding
      • Injection Molding
      • Insert molding
      • Mold Components
    • Tools
  • Materials
    • Advanced Materials
    • Metals
    • Nitinol
    • Plastics
    • Silicone
  • Business
    • Distribution Agreements
    • Legal News
    • Mergers & Acquisitions
    • Partnerships
    • Personnel Moves
  • Regulatory
    • 510(k)
    • CE Mark
    • FDA Breakthrough Designation
    • ISO Certification
    • Pre-Market Approval (PMA)
    • Recalls
  • Suppliers
  • About Us

MedAlliance’s Selution SLR wins FDA IDE approval for in-stent restenosis

October 25, 2022 By Danielle Kirsh

MedAlliance Selution SLR
[Image courtesy of MedAlliance]
MedAlliance today announced it received FDA investigational device exemption (IDE) approval for its Selution SLR to initiate its coronary pivotal clinical trial for in-stent restenosis.

Geneva-based MedAlliance’s Selution SLR is a drug-eluting balloon that is indicated for below-the-knee and superficial femoral artery (SFA) indications, for which it received IDE approval in May and August this year, respectively.

The device becomes one of the first sustained limus release coronary drug-eluting balloons (DEB) to receive FDA IDE approval for in-stent restenosis, according to MedAlliance. It has already begun enrollment in the trial in Europe.

“We are pleased with the speed of European enrollment and look forward to enrolling the first US patient before the year-end; US site selections are underway and will be finalized over the next several weeks. This study has the potential to address the important unmet need of a non-stent treatment for the ongoing problem of in-stent restenosis,” said Don Cutlip, principal investigator of the IDE study and chief medical officer at Baim Institute for Clinical Research.

In the coming weeks, MedAlliance plans to submit another IDE application for de novo coronary artery lesions to complement the substantial experience the company had with the Selution DeNovo trial in Europe.

MedAlliance last week announced that it would be acquired by Cordis for an initial $235 million. The total value of the deal could reach over $1.135 billion as Cordis will pay regulatory achievement milestones and commercial milestone payments.

About the clinical trial

More than 540 patients have been enrolled so far and the trial plans to enroll 3,326 patients in total. The study will compare Selution SLR to any limus drug-eluting stent to “demonstrate superiority” for coronary de novo artery disease.

“We have had significant success with enrollment of the larger randomized sister study, the international coronary Selution DeNovo study, and are excited to offer this new treatment option to US patients, avoiding permanent metal implants. No drug-coated balloon is currently approved in the U.S. for coronary indications,” CEO Jeffrey Jump said in a news release.

MedAlliance plans to begin enrollment in its IDE Selution4ISR FDA coronary study and start the trial in the U.S. later this year. The trial will, overall, be conducted at up to 60 centers worldwide and in up to 40 centers in the U.S.

Selution SLR has unique micro reservoirs that are made of biodegradable polymer intermixed with sirolimus. The micro reservoirs provide a controlled and permanent release of the drug for up to 90 days, while MedAlliance’s cell-adherent technology allows microdeposits to coat the balloons and adhere to the vessel lumen when delivered through an angioplasty balloon.

The device is commercially available in Europe, Asia, the Middle East and the Americas outside of the U.S. and most other countries where CE mark is recognized.

Filed Under: Balloons, Catheters, Regulatory Tagged With: MedAlliance

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Tubing + Extrusion, Medical Design & Outsourcing and MassDevice. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Primary Sidebar

“mte
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest trends and developments in medical tubing and extrusion.
MDO ad

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World
Drug Delivery Business News

Medical Tubing + Extrusion

Subscribe to our E-Newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS